Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kedar S, Kirtane"'
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6939772ad465d9853fdd5be6adc321b4
https://pubmed.ncbi.nlm.nih.gov/36509079
https://pubmed.ncbi.nlm.nih.gov/36509079
Autor:
Kea Turner, Angela M. Stover, Danielle B. Tometich, Carley Geiss, Arianna Mason, Oliver T. Nguyen, Emma Hume, Rachael McCormick, Sean Powell, Julie Hallanger-Johnson, Krupal B. Patel, Kedar S. Kirtane, Neelima Jammigumpula, Colin Moore, Randa Perkins, Dana E. Rollison, Heather S.L. Jim, Laura B. Oswald, Sylvia Crowder, Brian D. Gonzalez, Edmondo Robinson, Amir Alishahi Tabriz, Jessica Y. Islam, Scott M. Gilbert
Publikováno v:
JCO oncology practice.
PURPOSE: There has been limited study of the implementation of suicide risk screening for patients with head and neck cancer (HNC) as a part of routine care. To address this gap, this study assessed oncology providers' and professionals' perspectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227cc2207ef36d966f0f2555587020a2
https://pubmed.ncbi.nlm.nih.gov/36395441
https://pubmed.ncbi.nlm.nih.gov/36395441
Autor:
Yayi Zhao, Rossybelle P. Amorrortu, Rachel Howard, Kedar S. Kirtane, Susan T. Vadaparampil, Dana E. Rollison
Publikováno v:
Cancer Research. 83:5538-5538
Background: Racial/ethnic minority patients remain underrepresented in clinical trials potentially due to restrictive trial eligibility criteria that disproportionally affect minority cancer patients. Objective: To examine the prevalence of existing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77b18862b794d10a1d56c64f3f16bcb3
https://doi.org/10.1158/1538-7445.am2023-5538
https://doi.org/10.1158/1538-7445.am2023-5538
Publikováno v:
JCO Clin Cancer Inform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742ccf46c67b5b4e8d2093462107b279
https://doi.org/10.1200/cci.22.00013
https://doi.org/10.1200/cci.22.00013
Autor:
Anna Barata, Aasha I. Hoogland, Anuhya Kommalapati, Jennifer Logue, Taylor Welniak, Kelly A. Hyland, Sarah L. Eisel, Brent J. Small, Reena V. Jayani, Margaret Booth-Jones, Laura B. Oswald, Brian D. Gonzalez, Kedar S. Kirtane, Michael D. Jain, Sepideh Mokhtari, Julio C. Chavez, Aleksandr Lazaryan, Bijal D. Shah, Frederick L. Locke, Heather S.L. Jim
Publikováno v:
Transplant Cell Ther
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses in patients with relapsed/refractory hematologic malignancies. Immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e390d86606d513252f3b662b7fd4af3
https://doi.org/10.1016/j.jtct.2022.05.015
https://doi.org/10.1016/j.jtct.2022.05.015